Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $151K fell 42.4% year over year, ahead of the -48.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -42.4% holds above the trailing-twelve-month pace of -48.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 739K USD
- Year-over-year change
- -42.7%
- 4-year CAGR
- +8.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 739K | -42.7% |
| FY2024 | 2024-12-31 | 1.29M | -7.2% |
| FY2023 | 2023-12-31 | 1.39M | -2.6% |
| FY2022 | 2022-12-31 | 1.43M | +162.1% |
| FY2021 | 2021-12-31 | 544K | — |
Depreciation & Amortization vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 depreciation & amortization of $628K is the 8th highest of the 11 companies compared; the peer median is $2.07M.
- Its year-over-year change of -48.8% is the 9th highest of 11, against a peer median of -17.3%.
- Over three fiscal years its annual growth of -19.7% compares with a peer median of -9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $6.7M | -8.9% | -4.0% | 6.7% | |
| LTM Mar 2026 | $3.64M | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.64M | +6.6% | +30.9% | — |
| LTM Mar 2026 | $1.51M | -26.6% | -22.8% | — | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $398.22K | +164.2% | +454.8% | — | |
| LTM Mar 2026 | $291K | -90.7% | -55.3% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K | -88.5% | -20.8% | — |
| Peer median (excluding ZNTL) | $2.07M | -17.3% | -9.7% | 6.3% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 67.43M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 67.43M | 0 |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M |
| Selling, General & Admin | 40.94M | 54.55M | 59.4M | 87.12M | 37.72M |
| Operating Expenses | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| EBITDA | (207.2M) | (233.58M) | (247.6M) | (186.17M) | (144.27M) |
| EBITDA Margin | — | — | — | -276.1% | — |
| Operating Income | (216.54M) | (227.29M) | (299.51M) | (191.19M) | (152.81M) |
| Operating Margin | — | — | — | -283.6% | — |
| Interest Income | 0 | 2.26K | 0 | 0 | 0 |
| Interest Expense | 0 | 2.58M | 0 | 0 | 0 |
| Other Income / Expenses | 50.15M | (10.3M) | 6.6M | 25.5M | 16.19M |
| Income Before Tax | (166.39M) | (237.58M) | (292.91M) | (165.69M) | (136.62M) |
| Pre-Tax Margin | — | — | — | -245.7% | — |
| Income Tax Expense | (297K) | (469K) | (601K) | 177K | 442K |
| Net Income | (158.73M) | (236.81M) | (292.19M) | (165.84M) | (137.06M) |
| Net Margin | — | — | — | -246.0% | — |
| EPS (Basic) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| EPS (Diluted) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| Weighted Avg Shares | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
| Weighted Avg Shares (Diluted) | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.